SB 234551

a selective nonpeptide endothelin receptor antagonist

Also Known As:

(E)-alpha-1-butyl-5-(2-(2-carboxyphenyl)methoxy-4-methoxyphenyl)-1H-pyrazol-4-yl-methelene-6-methoxy-1,3-benzodioxole-5-propanoic acid; SB-234551

Networked: 4 relevant articles (1 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Pyrazoles: 61
      - SB 234551: 4
  - Dioxoles
    - SB 234551: 4

Experts

1.	Irving, Elaine A: 2 articles (07/2008 - 05/2005)
2.	Andrew A Parsons,: 1 article (07/2008)
3.	Barone, Frank C: 1 article (07/2008)
4.	Bentley, Ross G: 1 article (07/2008)
5.	Chandra, Sudeep: 1 article (07/2008)
6.	Haimbach, Robin E: 1 article (07/2008)
7.	Legos, Jeffrey J: 1 article (07/2008)
8.	Lenhard, Stephen C: 1 article (07/2008)
9.	McVey, Matthew J: 1 article (07/2008)
10.	Schaeffer, Thomas R: 1 article (07/2008)

Related Diseases

1.	Craniocerebral Trauma (Head Injury) 05/31/2005 - "In recent experimental studies, a selective antagonist of endothelin ET(A) receptors, SB 234551, improved neurological and histological outcome in both head trauma and transient focal cerebral ischemia. "
2.	Brain Ischemia (Cerebral Ischemia) 05/31/2005 - "A selective endothelin ET(A) receptor antagonist, SB 234551, improves cerebral perfusion following permanent focal cerebral ischemia in rats." 05/31/2005 - "In recent experimental studies, a selective antagonist of endothelin ET(A) receptors, SB 234551, improved neurological and histological outcome in both head trauma and transient focal cerebral ischemia. "
3.	Stroke (Strokes) 07/01/2008 - "SB 234551 selective ET(A) receptor antagonism: perfusion/diffusion MRI used to define treatable stroke model, time to treatment and mechanism of protection." 07/01/2008 - "In distal MCAO, SB 234551 administered immediately at the time of stroke did not have any effect on infarct volume in SHR. " 07/01/2008 - "When SB 234551 was administered within the period of peak mismatch (i.e., at 75 min post-stroke), SB 234551 provided significant dose-related reductions in cortical (penumbral) progression to infarction (p<0.05). " 11/01/2000 - "SB 234551 reduced focal stroke-induced neurological deficits by 50%, brain swelling by 54% and the degree of infarction by 36% (p < 0.05 at 30 mg/kg). " 11/01/2000 - "In this study, we evaluated changes in brain ET levels following closed head injury (CHI) and the effects of SB 234551, an endothelin-A- (ET(A)) selective antagonist, and SB 209670, a mixed endothelin-A- and -B- (ET(A)/ET(B)) antagonist, on outcome in CHI and focal stroke. "
4.	Closed Head Injuries 11/01/2000 - "In this study, we evaluated changes in brain ET levels following closed head injury (CHI) and the effects of SB 234551, an endothelin-A- (ET(A)) selective antagonist, and SB 209670, a mixed endothelin-A- and -B- (ET(A)/ET(B)) antagonist, on outcome in CHI and focal stroke. "
5.	Infarction (Infarctions) 07/01/2008 - "Also, when SB-234551 was administered beyond the time of mismatch, no effect on cortical penumbra progression to infarct was observed. " 07/01/2008 - "In distal MCAO, SB 234551 administered immediately at the time of stroke did not have any effect on infarct volume in SHR. " 07/01/2008 - "When SB 234551 was administered within the period of peak mismatch (i.e., at 75 min post-stroke), SB 234551 provided significant dose-related reductions in cortical (penumbral) progression to infarction (p<0.05). " 11/01/2000 - "SB 234551 reduced focal stroke-induced neurological deficits by 50%, brain swelling by 54% and the degree of infarction by 36% (p < 0.05 at 30 mg/kg). "

Related Drugs and Biologics

1.	Endothelins (Endothelin)
2.	(1S,2R,3S)- 1-(1,3-benzodioxol-5-yl)-3-(2- (carboxymethoxy)- 4- methoxyphenyl)- 2,3- dihydro- 5- propoxy- 1H-Indene-2-carboxylic acid
3.	enrasentan
4.	BQ 788

Related Therapies and Procedures

1.	Time-to-Treatment
2.	Intravenous Administration